Loading patent…
OwnerShafaat Ahmed Rabbani, Nicholas Shukeir +2inventors
InventorsShafaat Ahmed Rabbani, Nicholas Shukeir, Chandra J. Panchal, Christopher Newman
Estimating the term…
The present invention discloses the use of PSP-94 for treating a patient suffering from hypercalcemia of malignancy. Prostate secretory protein of 94 amino acids (PSP-94) is known to serve as prognostic marker in hormone-dependent prostate. In the current study the effect of PSP-94 on prostate cancer growth, metastases to the skeleton and hypercalcemia of malignancy was examined. A marked dose-dependent decrease in primary tumor volume was seen in experimental animals receiving PSP-94. Furthermore, while control animals routinely developed hypercalcemia due to PTHrP production, treatment with PSP-94 led to a near normalization of plasma calcium and a marked reduction in PTHrP production as determined by radioimmunoassay and immunohistochemistry. Results obtained demonstrate the ability of PSP-94 to be an effective treatment modality for prostate cancer. Furthermore, decrease in plasma PTHrP and calcium levels can serve as useful biochemical markers for monitoring the efficacy of this novel anti-tumor agent.
The use of PSP-94 for treating a patient suffering from hypercalcemia of malignancy.
The use of PSP-94 for reducing PTHrP levels in a patient in need thereof.
The use of PSP-94 to reduce the development of skeletal metastasis.
The use of PSP-94 in the manufacture of a pharmaceutical composition for the treatment of hypercalcemia of malignancy.
The use of PSP-94 in the manufacture of a pharmaceutical composition for the treatment of skeletal metastasis.
A method for evaluating, the efficacy of PSP-94 tumor treatment in a patient having a tumor, said method comprising measuring plasma calcium levels in said patient.
A method for evaluating, in a patient, the efficacy of PSP-94 treatment of hypercalcemia of malignancy, said method comprising measuring plasma calcium levels in said patient.
A method for evaluating, in a patient, the efficacy of PSP-94 treatment, said method comprising;
A method for evaluating, the efficacy of PSP-94 tumor treatment in a patient having a tumor, said method comprising measuring plasma PTHrP levels in said patient.
A method for evaluating, in a patient, the efficacy of PSP-94 treatment of hypercalcemia of malignancy, said method comprising measuring plasma PTHrP levels in said patient.
A method for evaluating, in a patient, the efficacy of PSP-94 treatment, said method comprising;
Dependencies are inferred from the claim text.